Nektar Therapeutics (NKTR) Stock Overview
NASDAQ · Healthcare · Biotechnology
✓ Sourced directly from Yahoo Finance · Checked for accuracy at every rebuild · Snapshot: 6 September 2026
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune…
Source: Yahoo Finance
Sector & Industry
Nektar Therapeutics operates in the Healthcare sector, within the Biotechnology industry group. It is listed on the NASDAQ exchange.
Nektar Therapeutics at a Glance
| Company | Nektar Therapeutics |
| Ticker | NKTR |
| Exchange | NASDAQ |
| Currency | USD |
| Price | $74.19 |
| Market cap | $2.53B |
| P/E ratio (trailing) | — |
| EPS (trailing) | -$6.12 |
| 52-week high | $109.00 |
| 52-week low | $33.40 |
| Dividend yield | — |
| Ex-dividend date | — |
| Beta | 1.15 |
| Return on equity (ROE) | -35.76% |
| Debt-to-equity | 15.05% |
| Average volume | 848,704 |
| Shares outstanding | 34.14M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 63 |
| Country | United States |
Investing Essentials
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Peter Lynch on how everyday investors can spot winners before the professionals do.
Check Price →Benjamin Graham's classic on value investing — the book Warren Buffett calls the best ever written on the subject.
Check Price →Evaluating pharma pipelines, devices and healthcare economics.
Check Price →Frequently Asked Questions
- What is Nektar Therapeutics's current P/E ratio?
- Nektar Therapeutics (NKTR) has a trailing P/E ratio of — as of our 6 September 2026 data snapshot. Learn what the P/E ratio means →
- What is Nektar Therapeutics's market capitalisation?
- Nektar Therapeutics's market cap is $2.53B based on our latest snapshot. See how it ranks by market cap →
- What is NKTR's 52-week range?
- Over the past 52 weeks, NKTR has traded between $33.40 and $109.00. What does the 52-week range mean? →
- How volatile is Nektar Therapeutics compared to the market?
- Nektar Therapeutics has a beta of 1.15, meaning it has historically moved more than the broader market. What does beta measure? →
- Does Nektar Therapeutics pay a dividend?
- Nektar Therapeutics does not currently pay a dividend according to our latest data.
- What exchange is NKTR listed on?
- NKTR is listed on the NASDAQ. Browse all NASDAQ-listed stocks →
- What sector is Nektar Therapeutics in?
- Nektar Therapeutics is classified in the Healthcare sector. Compare with Healthcare peers →
Need to convert currencies or units alongside this data? Our quick conversion tools are always on hand.
Many readers keep a stock investing journal to log positions and theses alongside pages like this one, and a dedicated financial calculator to hand for quick valuation maths.
Recommended Reading & Tools
Philip Fisher on what makes a business worth owning for the long term.
Check Price →Morgan Housel's short lessons on behaviour, luck and long-term wealth.
Check Price →Burton Malkiel's evidence-based guide to markets, indexing and long-term strategy.
Check Price →